BPMC Blueprint Medicines Corporation

58.04
-3.19  -5%
Previous Close 61.23
Open 59.3
Price To Book 6.76
Market Cap 3,135,727,602
Shares 54,027,009
Volume 843,370
Short Ratio
Av. Daily Volume 959,271
Stock charts supplied by TradingView

NewsSee all news

  1. Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis

    CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  2. Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020

    CAMBRIDGE, Mass., March 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reaffirmed

  3. Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting

    CAMBRIDGE, Mass., Feb. 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  4. Blueprint Medicines to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 19, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  5. Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results

    CAMBRIDGE, Mass., Feb. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 updated data presented March 16, 2020 - no patients discontinued treatment due to AEs. Enrolment in Part 2 of the PIONEER trial to be completed by the end of 2020.
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
FDA Approval announced January 9, 2020.
Avapritinib BLU-285
PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST)
Phase 1 updated data due in 2020.
BLU-667 - ARROW
RET-altered solid tumors
Phase 2 updated data due 2H 2020.
Avapritinib BLU-285 - PATHFINDER
Advanced Systemic mastocytosis (SM)
sNDA filing due 2H 2020.
Avapritinib - EXPLORER
Advanced Systemic mastocytosis (SM)
Phase 3 data due early 2Q 2020.
Avapritinib - Voyager
Gastrointestinal stromal tumors (GIST)
Phase 2 trial to be initiated 4Q 2019.
BLU-782
Fibrodysplasia ossificans progressiva (FOP)
Phase 3 trial initiation announced January 13, 2020.
Pralsetinib (BLU-667) - AcceleRET
First-line RET-fusion non-small cell lung cancer (NSCLC)
Rolling NDA has commenced. To be completed 1Q 2020.
Pralsetinib (BLU-667)
First-line RET-fusion non-small cell lung cancer (NSCLC)
Phase 1b/2 trial initiation announced January 6, 2020.
Fisogatinib and CS1001
Hepatocellular Carcinoma
NDA filing due 2Q 2020.
Pralsetinib (BLU-667)
RET-mutant medullary thyroid cancer
PDUFA date extended by three months to May 14, 2020 to allow for data from the Voyager trial.
Avapritinib
Fourth-line GIST

Latest News

  1. Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis

    CAMBRIDGE, Mass., March 16, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  2. Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020

    CAMBRIDGE, Mass., March 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reaffirmed

  3. Blueprint Medicines to Present Updated Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 2020 AAAAI Annual Meeting

    CAMBRIDGE, Mass., Feb. 24, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  4. Blueprint Medicines to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 19, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  5. Blueprint Medicines Reports Fourth Quarter and Full Year 2019 Financial Results

    CAMBRIDGE, Mass., Feb. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported

  6. Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020

    CAMBRIDGE, Mass., Feb. 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  7. Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor

    CAMBRIDGE, Mass., Feb. 6, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  8. Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., Jan. 22, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  9. Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

    CAMBRIDGE, Mass., Jan. 21, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  10. Blueprint Medicines Announces 2020 Corporate Goals

    CAMBRIDGE, Mass., Jan. 13, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  11. Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

    CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  12. Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer

    CAMBRIDGE, Mass., Jan. 8, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  13. CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

    SUZHOU, China and CAMBRIDGE, Mass., Jan. 6, 2020 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company focused on developing and commercializing immuno-oncology and precision

  14. Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested

    CAMBRIDGE, Mass., Dec. 8, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  15. Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced

  16. Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  17. Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its

  18. Blueprint Medicines to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced